Najla Alotaibi

Najla Alotaibi

Auto-generated profile, based on publicly available information

Najla Alotaibi

Internal Medicine, King Saud University Medical City, Riyadh, Saudi Arabia

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2025 in Journal of Diabetes Research
Verified
Journal Article
Open access
Abdullah M AlguwaihesAbdullah M Alguwaihes
Abdullah M Alguwaihes
NANajla Alotaibi
Najla Alotaibi
MAMetib Alotaibi
Metib Alotaibi
NMNaglaa Masry
Naglaa Masry
SSSaher Safarini
Saher Safarini
Aims: The study was aimed at assessing the role of the MiniMed780G system of glycemic control before, during, and after Ramadan among people with Type 1 diabetes (PwT1D). Methods: This is a single‐center retrospective analysis of MiniMed780G system users aged 14 years and above whose glycemic profiles were collected from February 21 to May 20, 2023, which corresponds to the Hijri months of Sha’ban, Ramadan, and Shawwal 1444/1445. Data was collected, processed, and analyzed in the framework of the Medtronic Galaxy service of the One Hospital Clinical Service (OHCS) program in Dallah Hospital, Riyadh, Saudi Arabia. Data from 43 PwT1D (24 females, mean age 30 ± 11 years with 14 ± 8 years from diabetes onset) using the MiniMed780G system were collected. Results: Overall, the 3‐month (Sha’ban, Ramadan, and Shawwal) mean sensor glucose (SG), time in range (TIR) (70–180 mg/dL), time below range (TBR) (54–69 mg/dL and < 54 mg/dL), time above range (TAR) (180–250 mg/dL and > 250 mg/dL), and glucose management indicator (GMI) showed no statistical differences within the three periods. No differences in insulin total daily dose have been detected, and no diabetic ketoacidosis (DKA) or severe hypoglycemia events occurred. Conclusion: The use of the MiniMed780G system is safe with favorable glycemic outcomes across nonfasting and fasting months.